nefazodone and mdl 100907

nefazodone has been researched along with mdl 100907 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Blatman-Jan, G; Dremencov, E; Kinor, N; Newman, ME; Overstreet, DH; Schindler, CJ; Yadid, G	1
Fava, M; Papakostas, GI	1
Papakostas, GI; Shelton, RC	1

Reviews

2 review(s) available for nefazodone and mdl 100907

Article	Year
A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. European psychiatry : the journal of the Association of European Psychiatrists, 2007, Volume: 22, Issue:7 Topics: Depressive Disorder, Major; Humans; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Antagonists; Trazodone; Triazoles	2007
Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta psychiatrica Scandinavica, 2008, Volume: 117, Issue:4 Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Dibenzothiazepines; Dopamine D2 Receptor Antagonists; Drug Resistance; Drug Therapy, Combination; Fluoxetine; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Serotonin 5-HT2 Receptor Antagonists; Thiazoles; Trazodone; Triazoles	2008

Article

Year

A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.

European psychiatry : the journal of the Association of European Psychiatrists, 2007, Volume: 22, Issue:7

Topics: Depressive Disorder, Major; Humans; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Antagonists; Trazodone; Triazoles

2007

Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder.

Acta psychiatrica Scandinavica, 2008, Volume: 117, Issue:4

Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Dibenzothiazepines; Dopamine D2 Receptor Antagonists; Drug Resistance; Drug Therapy, Combination; Fluoxetine; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Serotonin 5-HT2 Receptor Antagonists; Thiazoles; Trazodone; Triazoles

2008

Other Studies

1 other study(ies) available for nefazodone and mdl 100907

Article	Year
Hyperfunctionality of serotonin-2C receptor-mediated inhibition of accumbal dopamine release in an animal model of depression is reversed by antidepressant treatment. Neuropharmacology, 2005, Volume: 48, Issue:1 Topics: Analysis of Variance; Animals; Antidepressive Agents, Tricyclic; Depression; Desipramine; Disease Models, Animal; Dopamine; Extracellular Space; Male; Microdialysis; Models, Animal; Nucleus Accumbens; Piperazines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2C; Serotonin; Serotonin 5-HT2 Receptor Antagonists; Spiro Compounds; Staining and Labeling; Sulfonamides; Time Factors; Triazoles	2005

Article

Year

Hyperfunctionality of serotonin-2C receptor-mediated inhibition of accumbal dopamine release in an animal model of depression is reversed by antidepressant treatment.

Neuropharmacology, 2005, Volume: 48, Issue:1

Topics: Analysis of Variance; Animals; Antidepressive Agents, Tricyclic; Depression; Desipramine; Disease Models, Animal; Dopamine; Extracellular Space; Male; Microdialysis; Models, Animal; Nucleus Accumbens; Piperazines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2C; Serotonin; Serotonin 5-HT2 Receptor Antagonists; Spiro Compounds; Staining and Labeling; Sulfonamides; Time Factors; Triazoles

2005